DRI vs LXRX · P/E 22, rev $13.21B vs rev $21.8M
Darden Restaurants Inc (DRI) versus Lexicon Pharmaceuticals Inc (LXRX) — a side-by-side from cached financials, not a winner call.
Darden Restaurants Inc (DRI) is a restaurants company listed on NYSE.
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
Latest reported DRI revenue for 2026-05-31 was $13.21B. Net income was $1.21B. Revenue was up 9.4% from 2025-05-25 to 2026-05-31. DRI currently screens at market cap $24.20B and trailing P/E 22.3.
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
DRI currently screens at market cap $24.20B and trailing P/E 22.3. LXRX currently screens at market cap $327.2M.
Not investment advice. Open the DRI and LXRX stock pages for the full models.
Not investment advice.